Edition:
United States

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

5.80USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$5.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
384,137
52-wk High
$7.80
52-wk Low
$2.81

KERX.OQ

Chart for KERX.OQ

About

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the... (more)

Overall

Beta: 5.12
Market Cap(Mil.): $655.89
Shares Outstanding(Mil.): 105.96
Dividend: --
Yield (%): --

Financials

  KERX.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.56 -- --
ROI: -120.33 -1.09 14.95
ROE: -230.81 -2.39 16.29

BRIEF-Keryx Biopharmaceuticals says U.S. FDA approves second contract manufacturer for Auryxia

* Keryx biopharmaceuticals -patheon manufacturing services llc is now an fda approved drug product manufacturer of auryxia

Nov 09 2016

BRIEF-Keryx Biopharmaceuticals announces third quarter 2016 financial results

* Keryx Biopharmaceuticals announces third quarter 2016 financial results and provides corporate update

Nov 09 2016

BRIEF-Keryx Biopharmaceuticals files for mixed shelf of up to $250 million

* Keryx Biopharmaceuticals Inc - Files for mixed shelf of up to $250 million - SEC filing Source text: [http://bit.ly/2ff1wha] Further company coverage:

Nov 09 2016

BRIEF-Keryx Biopharmaceuticals and Patheon Manufacturing Services, it affiliates entered into a Master Manufacturing Services

* Keryx Biopharmaceuticals - Co, Patheon Manufacturing Services, it affiliates of entered into a Master Manufacturing Services, 2 product agreements

Oct 17 2016

Keryx withdraws 2016 forecast on renal drug supply disruption

Keryx Biopharmaceuticals Inc withdrew its full-year forecast due to a disruption in production of its only approved drug, Auryxia, sending its shares down by more than a third in morning trading on Monday.

Aug 01 2016

UPDATE 2-Keryx withdraws 2016 forecast on renal drug supply disruption

* Shares fall by a third (Adds analyst comment; updates shares)

Aug 01 2016

BRIEF-Keryx Biopharmaceuticals withdraws 2016 financial guidance

* Company announces interruption in supply of Auryxia(ferric citrate)

Aug 01 2016

Keryx withdraws 2016 forecast on renal drug supply interruption

Aug 1 Keryx Biopharmaceuticals Inc said it was withdrawing its full-year forecast due to issues related to the production of its only approved drug, Auryxia.

Aug 01 2016

BRIEF-Keryx Biopharmaceuticals appoints two new board members

* Keryx biopharmaceuticals appoints two new board members Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 21 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €75.04 -1.02
Fresenius Medical Care AG & Co. KGaA (FMEG.DE) €73.96 +0.94
Shire PLC (SHP.L) 4,604.00p -16.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates